FDA Approves Merck’s Enflonsia for RSV Prevention in Infants: Enflonsia (clesrovimab-cfor) is a long-acting monoclonal antibody approved to prevent respiratory syncytial virus (RSV) lower respiratory ...

Expanded Approval: Moderna’s mRESVIA vaccine is now FDA-approved for adults aged 18–59 years with an increased risk for respiratory syncytial virus (RSV)-related lower respiratory tract disease.

RAHWAY, N.J., June 09, 2025--U.S. FDA Approves Merck’s ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...

The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

Queensland’s Chief Health Officer has praised the new immunisation program that has protected hundreds of Queensland babies from Respiratory Syncytial Virus (RSV), as flu and Covid-19 cases ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

Researchers from Purdue University and the U.S. Centers for Disease Control and Prevention have recently developed a novel influenza vaccine candidate that uses a bovine adenoviral (BAd) vector to ...

COVID-19 transmission is still high in Pima County, with over 200 cases per 100,000 residents being reported; and eight-to-10 times more influenza cases are being reported across metro Tucson than ...